Stop wasting time & money !
Enjoy an unique one-stop-shop solution with dedicated experienced project manager: from animal housing to custom manufacturing up to several grams.
SYnAbs' custom monoclonal antibody generation service is a one-stop shop solution allowing the generation of high quality specific antibodies for in-vitro diagnostic, R&D and therapeutic purposes.
Over the years, SynAbs has accumulated extensive know-how in the generation of custom antibodies and the design & selection of antigens, such diverse as:
Neo-epitopes to detect specific protein cleavage sites,
Epigenetic modifications including methylated, phosphorylated and acetylated forms,
Small molecules (drugs...),
Bacteria, Viruses & Toxins (incl. low level detection),
High-homology antigens to distinguish between two closely related isoforms
(site specific mutations, substitution, deletion, insertion...),
Antibodies-related such as anti-idiotypes and anti-isotypes,
Difficult to express proteins (ion channel, GPCR),
As a complete service, SYnAbs is able to design, synthesize and conjugate antigens for use as immunogen for your monoclonal antibody development program. Using our in-house synthesis service, SYnAbs will assist you with the selection of antigenic epitope sections and the final peptide will be conjugated to a carrier protein to improve immunogenicity.
SYnAbs offers variable immunization schedules and injection routes to benefit from natural antibody maturity, while breaking immune tolerance for small molecules, peptides and low-immunogenic compounds.
SYnAbs maximizes the success rate and the quality of generated custom monoclonal antibody by applying parallel multi-species immunization strategy getting access to rat, mouse, and guinea pig immune repertoires.
Our expertise in the monitoring of antibody-mediated immune response is translated into recommendations prior to fusion step. Our customers are supplied with antiserum sample for screening purposes. In order to boost immune responses, SYnAbs has developed its proprietary special adjuvant.
SYnAbs has generated its own proprietary fusion cell lines in order to offer only stable and high productivity homo-hybridoma. After the fusion, cells are dispensed in 96 well plates (between 10 to 20, depending on initial number of cells). About two weeks later, hybridoma clones begin to appear. When the cells are in confluence, the supernatant will be tested by ELISA immuno-assay.
SYnAbs has developed a specific know-how to obtain a high efficiency electrofusion to generate a large number of positive hybridomas. The fusion is performed with all the spleen and poplitea lymph nodes to get an average of positives clones per target.
The supernatant of the positive clones will be immediately and regularly sent to your labs to be tested within a week by your own screening method. Your method can also be transferred to our labs at your convenience. 20 positives clones are kept and stored in nitrogen and each clone 3 vials and 10 ml of culture supernatant are prepared. The culture medium is composed by DMEM and FCS supplemented with HAT. After the clones' selection, the HAT is progressively eliminated. All your clones are isotyped and for chosen clones, a subcloning step by limit dilution is realized.
SYnAbs cell culture services offer animal-free tissue culture based protocols in shake-flasks, spinners, CELLines, and FiberCell and provide scale-up activities for large-scale manufacturing up to several grams. We also perform monoclonal antibodies purification and cell storage banking services.
|Up Stream Process mode||Quantity of Purified Antibody||Timelines|
|T-Flasks||2 mgrs||2 weeks|
|Spinner||20 mgrs||4 weeks|
|CELLine||200 mgrs||8 weeks|
|FiberCell||500 mgrs to several grams||12 weeks|
A large panel of Down-Stream process steps :
A large panel of Quality Controls on your batch :
Over the years, SYnAbs has developed a strong expertise in development of custom immunoassay and brings its expertise on the table for the optimization of your developed tests.
SYnAbs has a particular know-how to offer CDR grafting performance, humanization technique whereby humanized antibody sequences are generated by selecting CDRs of the parental antibody.